$6.38
-0.25-3.77%
Last update: Oct 30, 7:59 PM
Capricor Therapeutics Inc (CAPR) Stock Price, Quote, News & History
CAPRNASDAQ
Capricor Therapeutics (CAPR) shares top-line HOPE-3 extension data for Deramiocel in DMD ahead of its Nov 22 FDA PDUFA date.
You can purchase shares of Capricor Therapeutics (NASDAQ:CAPR) through any online brokerage.
Other companies in Capricor Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Capricor Therapeutics has a consensus price target of $30.86.
The stock price for Capricor Therapeutics (NASDAQ: CAPR) is $6.92 last updated October 30, 2026 at 7:59 PM EDT.
There are no upcoming dividends for Capricor Therapeutics.
Capricor Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Capricor Therapeutics.
Capricor Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in...
